Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Experts from AIIMS Delhi emphasised obesity’s harmful health effects and the need for preventive actions, supporting Prime ...

Spices alone cannot directly lead to weight loss, but some have properties that may help support your weight management plan.

"The increasing prevalence of cardiovascular conditions in younger people has many factors. Key contributors include obesity, ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...

President Prabowo Subianto’s universal free meals programme is well-intentioned, but it would be more effective if done in ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Central obesity measures of waist circumference and waist-to-hip ratio appear to be more accurate and consistent indicators of colorectal cancer incidence compared with BMI, according to a study ...